Últimos Artículos de Diabetes, Obesity and Metabolism
- A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin
- Reducing the need for carbohydrate counting in type 1 diabetes using closed‐loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non‐inferiority, crossover pilot trial
- Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: A pilot dose‐ranging study
- Beyond the myocardium: Sodium‐glucose co‐transporter‐2 inhibitors in heart failure
- Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial
- Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME
- Effects of 6 weeks treatment with dapagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: a randomized placebo‐controlled exploratory study
- Diabetes Duration and Glycemic Control as Predictors of Cardiovascular Disease and Mortality
- Long‐term (52‐week) efficacy and safety of dapagliflozin as adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT‐2 study
- Obesity as a driver of international differences in COVID‐19 death rates
- The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin‐resistant adults: A randomized trial
- The comparative effects of intensive glucose lowering in diabetes patients aged below or above 65 years: Results from the ADVANCE trial
- Real‐world evidence of bariatric surgery and cardiovascular benefits using electronic health records data: A lesson in bias
- Rates and estimated cost of primary care consultations in people diagnosed with type 2 diabetes and comorbidities: A retrospective analysis of 8.9 million consultations
- Advancing therapy with iGlarLixi versus Premix 70/30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomised controlled trial
- Safety and Efficacy of an Extended‐Release Peptide YY Analogue for Obesity: a Randomised, Placebo‐Controlled, Phase 1 Trial
- Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
- Meta‐analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium‐glucose co‐transporter‐2 inhibitors; implications for COVID19 pandemic.
- Sodium‐glucose cotransporter‐2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database
- Variability in eGFR and the risk of major clinical outcomes in diabetes: post‐hoc analysis from the ADVANCE trial